Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Cyclooxygenase-2 Expression is not a Marker of Poor Survival in Lung Cancer

  • Turk, H. Mehmet (Department of Medical Oncology, Faculty of Medicine, Gaziantep University) ;
  • Camci, Celalettin (Department of Medical Oncology, Faculty of Medicine, Gaziantep University) ;
  • Sevinc, Alper (Department of Medical Oncology, Faculty of Medicine, Gaziantep University) ;
  • Bukyukberber, Suleyman (Gazi University, Faculty of Medicine, Department of Medical Oncology) ;
  • Sari, Ibrahim (Department of Pathology, Faculty of Medicine, Gaziantep University) ;
  • Adli, Mustafa (Department of Radiation Oncology, Faculty of Medicine, Gaziantep University)
  • Published : 2012.01.31
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: Cyclooxygenase-2 (COX-2) has been claimed to play role in carcinogenesis and be related to a bad prognosis in tumours. The aim of this study was to investigate the relationship between COX-2 expression and clinical and pathological parameters in early and advanced stage lung cancer patients. Materials and Methods: A total of 73 patients with lung cancer (27 adenocarcinomas, 33 squamous cell carcinomas, 4 large cell carcinomas and 9 small cell cancer) were analysed retrospectively. COX-2 expression was evaluated by immunohistochemistry in resection materials or lung biopsies. Tumor cells demonstrating more intense staining than smooth muscle and endothelial cells were recorded as COX-2 positive. We investigated the correlation between increased COX-2 expression and histological type of the tumor, the stage of the disease and survival. Results: COX-2 expression was observed in 55% of the adenocarcinomas, 45% of the squamous cell carcinomas and 22% of the small cell carcinomas. No correlation was apparent between COX-2 expression and disease stage, histological type and the survival. Conclusion: The results of this study do not support COX-2 expression as an independent prognostic factor in lung cancer. However, since results of the literature are different, further studies made in larger series are needed.

Keywords

References

  1. Achiwa H, Yatabe Y, Hida T, et al (1999). Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res, 5, 1001-5.
  2. Altorki NK, Keresztes RS, Port JL, et al (2003). Celecoxib,a selective cyclo-oxygenase-2 infibitor,enhances the response to preoperative paclitaxel and carboplatin in early-stage non small cell lung cancer. J Clin Oncol, 21, 2645-50. https://doi.org/10.1200/JCO.2003.07.127
  3. Brabender J, Park J, Metzger R, et al (2002). Prognostic significance of cyclooxygenase 2 mRNA expression in non small cell lung cancer. Ann Surg, 235, 440-3. https://doi.org/10.1097/00000658-200203000-00017
  4. Castelao JE, Bart RD 3rd, DiPerna CA, et al (2003). Lung cancer and cyclooxygenase-2 Ann Thorac Surg, 76, 1327-35. https://doi.org/10.1016/S0003-4975(03)00334-5
  5. Denkert C, Köbel M, Pest S, et al (2002). Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carsinoma. Am J Pathol, 160, 893-903. https://doi.org/10.1016/S0002-9440(10)64912-7
  6. Duperron C, Castonguay A (1997). Chemopreventive efficacies of aspirin and sulindac against lung tumorigenesis in A/J mice. Carsinogenesis, 18, 1001-6. https://doi.org/10.1093/carcin/18.5.1001
  7. Edelman MJ, Watson D, Wang X, et al(2008). Eicosanoid modulation in advenced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy-- Cancer and Leukemia Group B Trial 30203. J Clin Oncol, 26, 848-55. https://doi.org/10.1200/JCO.2007.13.8081
  8. Fidler MJ, Argiris A, Patel JD, et al (2008). The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinid and celecoxib Clin Cancer Res, 14, 2088-94. https://doi.org/10.1158/1078-0432.CCR-07-4013
  9. Harris RE, Beebe-Donk J, Schuller HM (2002). Chemoprevention of lung cancer by non-steroidal anti-inflammatory drugs among cigarette smokers. Oncol Rep, 9, 693-5.
  10. Hida T, Kozaki K, Muramatsu H, et al (2000). Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res, 6, 2006-11.
  11. Hida T, Yatabe Y, Achiwa H, et al (1998). Incresed expression of cyclooxygenase 2 occurs frequently in human lung cancers , specifically in adenocarsinomas. Cancer Res, 58, 3761-4.
  12. Khuri FR, Wu H, Lee JJ, et al (2001). Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non small cell lung cancer. Clin Cancer Res, 7, 861-7.
  13. Masferrer JL, Leahy KM, Koki AT, et al (2000). Antiangigenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res, 60, 1306-11.
  14. Mascaux C, Martin B, Paesmans M, et al (2006). Has Cox-2 a prognostic role in non-small-cell lung cancer? A systematic review of the literature with meta-analysis of the survival results. Br J Cancer, 9, 139-45.
  15. Marrogi AJ, Travis WD, Welsh JA, et al (2000). Nitric oxide synthase, cyclooxigenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. Clin Cancer Res, 6, 4739-44.
  16. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, et al (2000). Antiangigenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res, 60, 1306-11.
  17. Mountain CF (2002). Staging classşfication of lung cancer. A critical evaluation. Clin Chest Med, 23, 103-21. https://doi.org/10.1016/S0272-5231(03)00063-7
  18. Milas L, Kishi K, Hunter N, et al (1999). Enhancemant of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme. J Natl Cancer Inst, 91, 1501-4. https://doi.org/10.1093/jnci/91.17.1501
  19. Nie D, Honn KV (2002). Cyclooxygenase, lipoxygenase and tumor angiogenesis. Cell Mol Life Sci, 59, 799-807. https://doi.org/10.1007/s00018-002-8468-9
  20. Ranger GS, Thomas V, Jewell A, et al (2004). Elevated cyclooxygenase-2 expression correlates with distant metastates in breast cancer. Anticancer Res, 24, 2349-51.
  21. Ristimaki A, Sivula A, Lundin J, et al (2002). Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res, 62, 632-5.
  22. Schreinemachers DM, Everson RB (1994). Aspirin use and lung, colon and breast cancer incidence in a prospective study. Epidemiology, 5, 138-46. https://doi.org/10.1097/00001648-199403000-00003
  23. Sinicrope FA, Gill S (2004). Role of cyclooxygenase-2 in colorectal cancer. Cancer Metastasis Rev, 23, 63-75. https://doi.org/10.1023/A:1025863029529
  24. Smith WL, Langenbach R (2001). Why there are two cyclooxygenase isozymes. J Clin Invest, 107, 1491-5. https://doi.org/10.1172/JCI13271
  25. Trifan OC, Durham WF, Salazar VS, et al (2002). Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. Cancer Res, 62, 5778-84.
  26. Travis WD, Travis LB, Devesa SS (1995). Lung cancer. Cancer, 75, 191-202. https://doi.org/10.1002/1097-0142(19950101)75:1+<191::AID-CNCR2820751307>3.0.CO;2-Y
  27. Tsubochi H, Sato N, Hiyama M, et al (2006). Combined analysis of cyclooxygenase-2 expression with p53 and Ki-67 in non-small cell lung cancer. Ann Thorac Surg, 82, 1198-204. https://doi.org/10.1016/j.athoracsur.2006.04.069
  28. Yao R, Rioux N, Castonguay A, et al (2000). Inhibition of COX-2 and induction of apoptosis: two determinants of antiinflammatory drugs chemopreventive efficacies in mouse lung tumorigenesis. Exp Lung Res, 26, 731-42. https://doi.org/10.1080/01902140150216783
  29. Zimmermann KC, Sarbia M, Weber AA, et al (1999). Cyclooxygenase-2 expresion in human esophageal carsinoma. Cancer Res, 59, 198-204.

Cited by

  1. Celecoxib attenuates cachectic events in mice by modulating the expression of vascular endothelial growth factor vol.11, pp.1, 2014, https://doi.org/10.3892/mmr.2014.2730
  2. New Insights on COX-2 in Chronic Inflammation Driving Breast Cancer Growth and Metastasis vol.20, pp.3-4, 2015, https://doi.org/10.1007/s10911-015-9333-4
  3. Impact and mechanism of non-steroidal anti-inflammatory drugs combined with chemotherapeutic drugs on human lung cancer-nude mouse transplanted tumors vol.11, pp.6, 2016, https://doi.org/10.3892/ol.2016.4493
  4. Differential expression of cyclooxygenase-2 and cyclin D1 in salivary gland tumors vol.275, pp.9, 2018, https://doi.org/10.1007/s00405-018-5058-5